摘要
心血管疾病和糖尿病肾病是糖尿病患者死亡的高危因素。在糖尿病临床管理中,平稳降糖的同时,也需要重视降低患者心血管风险和肾脏损伤的问题。新型降糖药物钠-葡萄糖共转运蛋白2抑制剂(SGLT2i),除降糖之外兼具减重、降压和改善代谢的作用,还被证明在具有心血管风险和确诊心血管疾病的2型糖尿病(T2DM)患者中能降低心血管及肾脏事件的发生风险。SGLT2i的心、肾获益机制引起了广泛关注但仍未明确,本文将针对SGLT2i的心脏和肾脏保护作用及其潜在机制进行综述。
Cardiovascular disease and diabetic kidney disease are high risk factors for death in patients with diabetes.It is necessary to pay attention to reducing the cardiovascular risk and kidney injury of patients while maintaining stable glucose control in the clinical management of diabetes.Sodium-glucose cotransporter 2 inhibitors(SGLT2i)are a novel class of antidiabetic agents,which have the effect of reducing weight,lowering blood pressure and improving metabolism in addition to lowering blood glucose,have also been shown to reduce risk of cardiovascular and renal events in type 2 diabetes patients with or at risk for cardiovascular disease.The cardiorenal benefits of SGLT2i have attracted widespread attention but the mechanisms are not yet clear.This review focuses on the cardiovascular and renal protective effects of SGLT2i and their potential mechanisms.
作者
林毅
彭永德
LIN Yi;PENG Yongde(Department of Endocrinology and Metabolism,Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200080,China)
出处
《药品评价》
CAS
2020年第18期1-4,12,共5页
Drug Evaluation
